Scotiabank has highlighted three biotechnology companies as its "top picks," each with the potential to more than double in stock price over the next 12 months. The bank's optimism for these companies and the broader biotechnology sector is partly based on anticipated changes in the macroeconomic environment. The investment bank expects shares to rise to $50 over the next 12 months, or 165% from the current share price. RCKT 1Y line Liquidia Corp Scotiabank is optimistic about the company's Yutrepia treatment for pulmonary arterial hypertension, set to launch in May 2025. Scotiabank expects shares to rise by nearly 170% to $30 a share over the next 12 months.

---

Persons: Greg Harrison, Harrison, LQDA, OCUL Organizations: Scotiabank, Rocket Pharmaceuticals, Liquidia Corp, Rocket Pharmaceuticals Scotiabank, Liquidia Corp Scotiabank, National Health Service